<DOC>
	<DOCNO>NCT01763242</DOCNO>
	<brief_summary>Aims : 1 . To establish electronic process CKD anaemia management use monthly synchronize dose erythrocyte stimulating agent ( ESA ) . 2 . To compare electronic process `` present anaemia management '' traditional outpatient setting . 3 . To monitor Hb target clinical endpoint study group model large multicentre study focus endpoint .</brief_summary>
	<brief_title>Study Effect Synchronised Anaemia Management Chronic Kidney Disease</brief_title>
	<detailed_description>CKD Stages 3 5 Subjects randomise stratified accord Age , Gender , CKD Stage , Known Cardiovascular Disease , Diabetes ESA Type EMAN vs. Control Details EMAN synchronization Dosing : Monthly dose ESA calculate : Monthly dose = present dose x ( 28/present frequency ( day ) ) Synchronization achieve use formula : `` Synchronization dose ESA = ( 28-Days next injection due ) /28 x monthly dose ESA The dose ESA/C.E.R.A . adjust maintain individual patient 's haemoglobin within range 11± 1.0 g/dL reference haemoglobin concentration ie . 10.0 12.0 g/dL Haemoglobin Value Corrective Adjustment - A single value &gt; 13 g/dL Interrupt treatment Hb fall 12 g/dL re-start treatment 50 % previous dose - A single value &lt; 9 g/dL Increase dose 50 % - Difference two consecutive Hb value indicate ≥2 g/dL increase Reduce dose 50 % - Difference two consecutive Hb value indicate ≥2 g/dL decrease Increase dose 50 % - &gt; 11.5 g/dL &lt; 13 g/dL AND deviation reference value &gt; 1g/dL . Reduce dose 25 % - &lt; 10.5 g/dL &gt; 9 g/dL AND deviation reference value &gt; 1g/dL . Increase dose 25 % - &gt; 12 g/dL Reduce dose 25 % - &lt; 10 g/dL Increase dose 25 % Statistics : Audit present practice suggest CKD patient achieve 30 % target ( Hb 10-12g/dL ) well audited dialysis unit service achieve 60 % target . If improvement 30 % 60 % expect EMAN verse Control arm 100 patient ( 50 group ) would require show significant difference p &lt; 0.05 85 % power . Patients analysed intention treat basis Primary Secondary Endpoint data compare study control group use unpaired student t-tests normalisation data require and/or chi square analysis . Statistical significance take p &lt; 0.05 .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Written inform consent Age &gt; 18 year Chronic renal anaemia already ESA therapy define Pharmaceutical Benefits Scheme Criteria Pregnancy Significant acute bleed overt gastrointestinal bleed A known haematological cause anaemia Known metastatic malignancy Present participation another interventional clinical trial • Known hypersensitivity recombinant human erythropoietin , polyethylene glycol constituent study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>CKD , Anaemia , Synchronization , Monthly dosing , Home Delivery</keyword>
</DOC>